4//SEC Filing
de Notaristefani Carlo 4
Accession 0001209191-19-010835
CIK 0000818686other
Filed
Feb 18, 7:00 PM ET
Accepted
Feb 19, 7:05 AM ET
Size
10.0 KB
Accession
0001209191-19-010835
Insider Transaction Report
Form 4
de Notaristefani Carlo
Executive VP Global Operations
Transactions
- Exercise/Conversion
Ordinary Shares
2019-02-14+9,280→ 21,400.727 total - Sale
Ordinary Shares
2019-02-14$17.67/sh−3,192$56,399→ 18,208.727 total - Exercise/Conversion
Restricted Share Units
2019-02-14−9,280→ 18,560 total→ Ordinary Shares (9,280 underlying)
Footnotes (6)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- [F3]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F4]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.66 to $17.675, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F6]Restricted share units were granted on February 14, 2017, with 9,280 vesting on each of February 14, 2019, February 14, 2020 and February 14, 2021.
Documents
Issuer
TEVA PHARMACEUTICAL INDUSTRIES LTD
CIK 0000818686
Entity typeother
Related Parties
1- filerCIK 0001719114
Filing Metadata
- Form type
- 4
- Filed
- Feb 18, 7:00 PM ET
- Accepted
- Feb 19, 7:05 AM ET
- Size
- 10.0 KB